An innovative blood-testing approach helped bring approximately one in four high-risk patients who previously declined lung cancer screening back into the recommended screening process.

What if a simple blood test could help bring more patients into potentially lifesaving lung cancer screening?

That question is at the center of new research from OSF HealthCare Cancer Institute, presented at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain.

Jun Zhang, MD, PhD, vice president of Oncology Research at OSF HealthCare Cancer Institute, delivered a rapid oral presentation highlighting findings from a multi-site study investigating how an innovative blood-testing approach may help more high-risk patients complete recommended lung cancer screening.

The findings offer an encouraging new perspective on one of the biggest challenges in early cancer detection: reaching patients who might otherwise remain unscreened.

Finding New Ways to Reach Patients

Lung cancer screening can save lives by detecting the disease earlier, when treatment is often more effective. Yet many people at high risk of developing lung cancer do not complete recommended screening.

Low-dose computed tomography (LDCT) is the recommended screening examination for eligible high-risk individuals. However, barriers such as transportation, scheduling difficulties, concerns about radiation, and limited access to imaging services can prevent patients from participating.

These challenges can be particularly significant in rural communities.

To explore a different approach, OSF researchers evaluated FirstLook Lung, a blood test developed by DELFI Diagnostics that uses cell-free DNA fragmentomics, a technology that analyzes patterns in small fragments of DNA circulating in the bloodstream.

The goal is not to replace recommended CT screening, but to investigate whether a simple blood test could encourage more patients to take that important next step.

Encouraging Results from OSF Research

The study included 251 patients across urban and rural Illinois communities who had previously declined recommended lung cancer screening.

All 251 participants completed blood-based testing. Of those patients, 100 had elevated results, and 65 subsequently completed the LDCT examination they had previously declined.

Among those who completed imaging, 11 had findings requiring additional evaluation or follow-up, including two patients referred for oncology evaluation.

Overall, approximately one in four patients who previously declined recommended lung cancer screening went on to complete LDCT after participating in the blood-testing pathway.

These preliminary findings suggest that blood-based prescreening may offer an additional way to engage patients who otherwise might remain outside established screening programs.

Importantly, an elevated blood-test result or abnormal CT finding does not necessarily mean a patient has cancer. Further research is needed to determine whether this approach improves cancer detection rates or long-term health outcomes.

Advancing Early Detection for More Communities

The findings presented at ESMO 2026 highlight how research conducted within a community-based health system can contribute to international scientific efforts to advance cancer screening and early detection.

At OSF HealthCare Cancer Institute, this work reflects a broader commitment to connecting scientific innovation with practical approaches that expand access to care, particularly for rural and underserved communities.

Through its Breakthrough Treatment Center and growing research programs, OSF continues to investigate new technologies and strategies that may help more patients benefit from advances in cancer detection and treatment.

The ultimate goal is simple: reach more patients, improve participation in recommended screening, and create more opportunities to detect cancer when treatment may be most effective.

This article describes preliminary research findings presented at ESMO 2026. Blood-based prescreening is a complementary approach under investigation and does not replace recommended low-dose CT screening. Patients should consult their healthcare provider about appropriate screening options.